Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.33
At close: Jun 30 EDT
$6.31
-0.02-0.32%
Pre-Market: 7:50 AM EDT
Comments
Loading...
Amylyx Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AMLX | Benzinga
Amylyx Pharmaceuticals Inc has a consensus price target of $24.17 based on the ratings of 13 analysts. The high is $54 issued by Citigroup on March 14, 2023. The low is $4 issued by Goldman Sachs on July 12, 2024. The 3 most-recent analyst ratings were released by Guggenheim, Citigroup, and Mizuho on June 24, 2025, June 17, 2025, and May 14, 2025, respectively. With an average price target of $12.33 between Guggenheim, Citigroup, and Mizuho, there's an implied 95.46% upside for Amylyx Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Citigroup
Mizuho
HC Wainwright & Co.
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Amylyx Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | 169.41% | Guggenheim | Seamus Fernandez67% | → $17 | Initiates | → Buy | Get Alert |
| 06/17/2025 | Buy Now | 90.17% | Citigroup | Geoff Meacham62% | → $12 | Initiates | → Buy | Get Alert |
| 05/14/2025 | Buy Now | 26.78% | Mizuho | Graig Suvannavejh51% | $7 → $8 | Maintains | Outperform | Get Alert |
| 05/09/2025 | Buy Now | 153.57% | HC Wainwright & Co. | Andrew Fein61% | $12 → $16 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 58.48% | Leerink Partners | Marc Goodman73% | $4 → $10 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/07/2025 | Buy Now | 10.94% | Mizuho | Graig Suvannavejh51% | $3 → $7 | Upgrade | Neutral → Outperform | Get Alert |
| 03/05/2025 | Buy Now | 90.17% | HC Wainwright & Co. | Andrew Fein61% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 90.17% | HC Wainwright & Co. | Andrew Fein61% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 74.33% | Baird | Joel Beatty68% | $3 → $11 | Upgrade | Neutral → Outperform | Get Alert |
| 11/08/2024 | Buy Now | 90.17% | HC Wainwright & Co. | Andrew Fein61% | $8 → $12 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | -36.61% | Goldman Sachs | Chris Shibutani54% | $3 → $4 | Maintains | Neutral | Get Alert |
| 07/10/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | -52.46% | Mizuho | Graig Suvannavejh51% | $4 → $3 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | -52.46% | Baird | Joel Beatty68% | $4 → $3 | Maintains | Neutral | Get Alert |
| 04/08/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $8 → $8 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 26.78% | HC Wainwright & Co. | Andrew Fein61% | $42 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 26.78% | Deutsche Bank | Neena Bitritto-Garg57% | $36 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | -36.61% | Goldman Sachs | Chris Shibutani54% | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 03/11/2024 | Buy Now | — | Leerink Partners | Marc Goodman73% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/11/2024 | Buy Now | -36.61% | Baird | Joel Beatty68% | $37 → $4 | Downgrade | Outperform → Neutral | Get Alert |
| 03/08/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat42% | — | Downgrade | Outperform → In-Line | Get Alert |
| 03/08/2024 | Buy Now | 407.13% | Mizuho | Graig Suvannavejh51% | $27 → $32 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 486.37% | Baird | Joel Beatty68% | → $37 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | Buy Now | 327.89% | Mizuho | Graig Suvannavejh51% | $46 → $27 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 470.52% | Deutsche Bank | Neena Bitritto-Garg57% | → $36 | Initiates | → Buy | Get Alert |
| 11/10/2023 | Buy Now | 533.91% | Goldman Sachs | Chris Shibutani54% | $46 → $40 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 565.61% | HC Wainwright & Co. | Andrew Fein61% | $50 → $42 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 676.55% | Goldman Sachs | Chris Shibutani54% | $45 → $49 | Upgrade | Neutral → Buy | Get Alert |
| 05/31/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 692.39% | Mizuho | Graig Suvannavejh51% | $52 → $50 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2023 | Buy Now | 724.09% | Mizuho | Graig Suvannavejh51% | → $52 | Initiates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 644.85% | Goldman Sachs | Chris Shibutani54% | $41 → $47 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 755.78% | Citigroup | Itay Michaeli46% | $51 → $54 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | → $50 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 692.39% | B of A Securities | Geoff Meacham62% | → $50 | Initiates | → Buy | Get Alert |
| 10/24/2022 | Buy Now | 692.39% | HC Wainwright & Co. | Andrew Fein61% | $35 → $50 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 692.39% | Citigroup | Neena Bitritto-Garg57% | $48 → $50 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | 533.91% | Goldman Sachs | Chris Shibutani54% | $22 → $40 | Maintains | Neutral | Get Alert |
| 09/08/2022 | Buy Now | 660.7% | Citigroup | Neena Bitritto-Garg57% | $35 → $48 | Maintains | Buy | Get Alert |
| 09/08/2022 | Buy Now | 692.39% | SVB Leerink | Marc Goodman73% | $31 → $50 | Maintains | Outperform | Get Alert |
| 07/06/2022 | Buy Now | 486.37% | Citigroup | Neena Bitritto-Garg57% | $33 → $37 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Amylyx Pharmaceuticals (AMLX) stock?
The latest price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) was reported by Guggenheim on June 24, 2025. The analyst firm set a price target for $17.00 expecting AMLX to rise to within 12 months (a possible 169.41% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amylyx Pharmaceuticals (AMLX)?
The latest analyst rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) was provided by Guggenheim, and Amylyx Pharmaceuticals initiated their buy rating.
When was the last upgrade for Amylyx Pharmaceuticals (AMLX)?
The last upgrade for Amylyx Pharmaceuticals Inc happened on May 7, 2025 when Leerink Partners raised their price target to $10. Leerink Partners previously had a market perform for Amylyx Pharmaceuticals Inc.
When was the last downgrade for Amylyx Pharmaceuticals (AMLX)?
The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Amylyx Pharmaceuticals (AMLX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharmaceuticals was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating Amylyx Pharmaceuticals (AMLX) correct?
While ratings are subjective and will change, the latest Amylyx Pharmaceuticals (AMLX) rating was a initiated with a price target of $0.00 to $17.00. The current price Amylyx Pharmaceuticals (AMLX) is trading at is $6.31, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
